Monte Rosa Therapeutics, Inc. - GLUE
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 19, 2026 | SCHEDULE 13D/A | — | 1.0% | — | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 3.1% | 2,050,405 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 3.1% | 2,050,405 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 2.3% | 1,496,859 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 2.3% | 1,496,859 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.4% | 232,097 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.4% | 232,097 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 5.4% | 3,547,264 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 5.9% | 3,835,886 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF INC/IL | 5.9% | 3,835,886 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 5.9% | 3,835,886 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Baker Bros. Advisors LP | 6.7% | 4,345,736 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Baker Bros. Advisors (GP) LLC | 6.7% | 4,345,736 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Julian C. Baker | 6.7% | 4,345,736 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Felix J. Baker | 6.7% | 4,345,736 | View |
| Jan 21, 2026 | SCHEDULE 13G/A | Adam Goulburn | 8.7% | 5,663,265 | View |
| Jan 21, 2026 | SCHEDULE 13G/A | Zavain Dar | 8.7% | 5,663,265 | View |
| Jan 21, 2026 | SCHEDULE 13G/A | Nan Li | 8.7% | 5,663,265 | View |
| Jan 21, 2026 | SCHEDULE 13G/A | Dimension Management, L.P. | 8.7% | 5,663,265 | View |
| Jan 21, 2026 | SCHEDULE 13G/A | Dimension Capital I GP, LLC | 8.7% | 5,663,265 | View |
| Jan 21, 2026 | SCHEDULE 13G/A | Dimension Management GP, LLC | 8.7% | 5,663,265 | View |
| Jan 21, 2026 | SCHEDULE 13G/A | Dimension Capital I, L.P. | 8.7% | 5,663,265 | View |
| Jan 09, 2026 | SCHEDULE 13D/A | — | 4.99% | — | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Avoro Capital Advisors LLC | 0.0% | 0 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Behzad Aghazadeh | 0.0% | 0 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | T. Rowe Price Associates, Inc. | 7.5% | 4,637,060 | View |
| Nov 12, 2025 | SCHEDULE 13D/A | — | — | — | View |
| Oct 31, 2025 | SCHEDULE 13G/A | The Vanguard Group | 4.83% | 2,988,953 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.